AMENDMENTS

In the claims:

Please amend claim 22 as follows:

By Sub CA

22. (Once amended) A composition comprising cells labeled by the method according to claim 21.

REMARKS

Claims 1-73 are pending in the present application. Claims 51-73 were previously withdrawn from consideration as being drawn to non-elected invention. Claim 22 has been amended for clarity. Attached hereto is a marked up version of the changes made to the claims by the current amendment with additions underlined and deletions bracketed. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE**."

Applicants acknowledge withdrawal of the Section 102(b) rejection of claims over Manz et al. and Section 102(b) rejection of claims over Miltenyi et al.

Rejections under 35 U.S.C. § 112, first paragraph

Claims 1-50 stand rejected under 35 U.S.C. § 112, first paragraph. The Examiner maintains the rejection alleging that the specification does not provide reasonable enablement for methods which do not recite a high viscosity or gel forming medium.

Applicants strongly disagree and traverse this rejection of claims. Applicants submit that the specification teaches methods that distinguish product secreting T cells from non-product secreting T cells and provides several illustrative examples of such methods performed in the absence of high viscosity or gel forming medium. The incubation medium can optionally include a substance that slows diffusion of the product from the producer cell.

The specification at page 44, under Example 1, describes the enrichment of IFN- γ-secreting cells with the magnetic cell separation system, MACS, from peripheral blood mononuclear cells (PBMC) cultured in peptide MI 58-66 from Influenza virus matrix. As disclosed at page 44, lines 13-18, the cells were cultured in media containing complete RPMI 1640 containing 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.3 mg/ml glutamine, 10 mM 2-